Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Molecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH ‐wildtype
Carabenciov, Darin D., Trejo‐Lopez, Jorge , Nguyen, Aivi T. , Ida, Cristiane M. , Zepeda‐Mendoza, Cinthya , Dasari, Surendra , Russler-Germain, Emilie V. , Quezado, Martha , Aldape, Kenneth , Giannini, Caterina, Zhu, Yi , Trejo-Lopez, Jorge A, Ida, Cristiane M , Russler-Germain, Emilie , Dahiya, Sonika , Nguyen, Aivi T , Johnson, Derek R. , Raghunathan, Aditya , Lanzino, Giuseppe , Dahiya, Sonika

Mayo Clinic

Brain Pathology | December 18, 2024 | Volume: 35 | Issue: 4 | Pages: No page available

10.1111/bpa.13326 | PMID 39692003 Get It

Abstract Adult primary leptomeningeal gliomatosis (PLG) is a rare, rapidly progressive and fatal disease characterized by prominent leptomeningeal infiltration by a glial tumor without an identifiable parenchymal mass. The molecular profile of adult PLG has not been well‐characterized. We report the clinical, pathological, and molecular findings of six adult PLG patients (five males and one female), median age 58 years. All cases exhibited pathological leptomeningeal enhancement at presentation. Leptomeningeal biopsy was diagnostic in five (of six) cases, revealing infiltration by an astrocytic glioma with mitotic activity, lacking microvascular proliferation or necrosis. One case was diagnosed at autopsy. All tumors were IDH‐wildtype, with five harboring TERT promoter mutations. Additional mutations identified were PTEN in one case, TP53 in two cases, and NF1 in two cases. A chromosome profile with +7/−10 was found in four cases, whereas the remaining two showed either chromosome 7 or 7p gain only. Four cases showed chromosome 9p loss with CDKN2A/B homozygous deletion, one case showed hemizygous CDKN2A/B loss, and one case showed intact chromosome 9 and CDK4/GLI1 amplification. DNA methylation profiling was performed in four cases and revealed a match to glioblastoma (GBM) family and mesenchymal typical class with high confidence scores in two cases; the other two cases showed only suggestive combined scores for GBM family and mesenchymal atypical class. The molecular profile of all cases closely aligned with that of adult‐type GBM, IDH‐wildtype, CNS WHO grade 4. All patients succumbed to the disease. In five cases with extensive leptomeningeal disease at diagnosis, the course was rapid, with median survival of 24 days following palliative care. Only one case, with relatively localized disease at diagnosis, received chemoradiation therapy and survived 535 days, raising the possibility that early diagnosis and timely treatment could improve outcome. A detailed list of previously reported cases is provided in a supplementary table.
Federated Learning for Enhanced ECG Signal Classification with Privacy Awareness
Nguyen, Linh Thi Hoai , Zhang, Lan , Nguyen, Tuy Tan , Phan, Quoc Bao , Nguyen, Linh, Bui, Ngoc Thang , Nguyen, Dinh C.

Mayo Clinic

2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | December 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/embc53108.2024.10782098 | PMID 40039001 Get It

Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience
Marell, Paulina S. , Peersen, Anina, Shah, Priyanshi , Kankeu, Lionel Fonkoua, Washburn, Leslie, Truty, Mark J. , Jatoi, Aminah , Marell, Paulina, Kournoutas, Ioannis , Gile, Jennifer , Truty, Mark, Starlinger, Patrick , Halfdanarson, Thorvardur, Jin, Zhaohui , Jatoi, Aminah , McWilliams, Robert, Ou, Fang-Shu , Tran, Nguyen , Babiker, Hani M. , Fonkoua, Lionel Aurelien Kankeu , Graham, Rondell P. , Starlinger, Patrick , Hálfdánarson, Þorvarður R. , Jin, Zhaohui , McWilliams, Robert R. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Mahipal, Amit , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

The Oncologist | December 14, 2024 | Volume: 30 | Issue: 8 | Pages: No page available

10.1093/oncolo/oyae342 | PMID 39674576 Get It

Abstract Background Atezolizumab plus bevacizumab (A/B) received FDA approval as the first-line therapy for patients with advanced hepatocellular carcinoma (HCC) in 2020. However, optimal subsequent treatment options are unclear. Here, we describe clinical outcomes of advanced HCC patients following first-line treatment with A/B. Patients and Methods We conducted a multi-site analysis of patients with HCC treated with first-line A/B between January 2018 and December 2022 at Mayo Clinic. This study cohort included all patients receiving second-line systemic therapy after A/B. Median overall survival (OS) and time-to-treatment discontinuation (TTD) were estimated using the Kaplan-Meier method. Child Pugh (CP) scores are also described at diagnosis, prior to first line, and prior to second-line therapy. Results Of the 342 patients who received A/B, 107 (31.3%) received second-line treatments including anti-VEGF therapy or immune checkpoint inhibitor (ICI) and were included in the final analysis. Median OS for all patients was 11.1 months from initiation of second-line therapy. Median OS was 10.7 months (95% CI: 7.2-12.8) and 15.7 months (95%CI: 6.8-NE) for those receiving anti-VEGF inhibitors and ICI ( P = .50). Median TTD for second-line therapies was 2.4 months (95% CI: 1.7-3.3) and 2.6 months (95% CI: 1.5-5.1) for anti-VEGF inhibitors and ICI, respectively (P = .87). In multivariate analyses, CP was significantly associated with survival. Conclusion Following first-line A/B treatment, there is no statistically significant difference in survival between ICI and anti-VEGF therapy, nor in time to treatment discontinuation. CP score remains an important prognostic tool.
Transgender Healthcare
Sparks, Payton J., Bozigar, Caden, Shah, Krish V., Wan, Rou , Uryga, Abigail, Nguyen, Antoinette T. , Li, Rena A. , Sparks, Payton J., Shah, Krish V., Galiano, Robert D.

Mayo Clinic

Annals of Plastic Surgery | December 12, 2024 | Volume: 94 | Issue: 1 | Pages: 128-133

10.1097/sap.0000000000004161 | PMID 39665456 Get It

Abstract This historical narrative presents a comprehensive historical journey delving into the diverse facets of gender identity and expression across ancient cultures. It explores these civilizations' perspectives on gender diversity, highlighting instances that challenged conventional gender norms. Transitioning to the modern era, the narrative examines the dynamic landscape of LGBTQ+ and trans movements, spotlighting influential figures whose advocacy has significantly influenced societal perceptions and advanced the rights of gender diverse individuals. Their contributions continue to shape contemporary affirming care practices. Exploring the emergence of gender-affirming surgery, the narrative highlights pioneering surgeons and original techniques employed in these transformative procedures. It shows the courage and innovation of early surgeons who laid the groundwork for contemporary practices. At the core of this historical narrative lies the pivotal role of plastic surgeons in gender-affirming care. It emphasizes the significance of a collaborative multidisciplinary approach among medical professionals to ensure comprehensive and patient-centered care for transgender individuals seeking affirming interventions. However, intertwined with this narrative are legislative barriers that have hindered progress in gender-affirming care. The narrative navigates these obstacles, highlighting their complexities and emphasizing the urgent need for sustained medical advocacy and legislative reforms to foster an inclusive healthcare landscape. Ultimately, this narrative stands as a testament to the ongoing struggle and resilience within the realm of gender-affirming care, shedding light on its profound impact on individuals' lives, emphasizing the ongoing need for compassionate, comprehensive, and inclusive healthcare practices.
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Antonelli, Luca , Heidenreich, Axel , Baky, Fady , Branger, Nicolas , Daneshmand, Siamak , Djaladat, Hooman , Eggener, Scott E. , Sexton, Wade J. , Nicol, David , Olson, Kathleen, Paffenholz, Pia , Porter, James , Qian, Zhiyu , Rocco, Nicholas R., Stroup, Sean P. , Tachibana, Isamu , Cary, Clint , Daneshmand, Siamak , Djaladat, Hooman , Ghoreifi, Alireza , Nicol, David , Nicolai, Nicola , Paffenholz, Pia , Porter, James , Stroup, Sean P , Fankhauser, Christian Daniel , Bagrodia, Aditya , Amini, Armon , Cazzaniga, Walter , Clinton, Timothy Nguyen , Ghoreifi, Alireza , Hamilton, Robert J , Ho, Matthew, Nazzani, Sebastiano , Olson, Kathleen, Yerrapragada, Anirudh , Terbuch, Angelika , Singla, Nirmish

Mayo Clinic

BJU International | December 11, 2024 | Volume: 135 | Issue: 4 | Pages: 621-628

10.1111/bju.16618 | PMID 39662898 Get It

Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker‐negative non‐seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications. Materials and Methods Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease‐free survival (DFS). Results A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01–1.07; P = 0.03), but no association was observed with DFS. The 5‐year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non‐teratomatous viable cancer in the RPLND specimen, the 5‐year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS. Conclusions Our study suggests considering primary RPLND not only in marker‐negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker‐positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Guan, Li , Torres‐Saavedra, Pedro A. , Zhao, Xiaobei , Major, Michael B. , Holmes, Brittany , Nguyen, Ngan K. , Kumaravelu, Parasakthy , Hodge, Tim , Diehn, Maximilian , Zevallos, Jose P. , Emami, Bahman, Hayward, Michele C. , Sagar, Stephen M. , Morrison, William H. , Schultz, Christopher J. , Jones, Christopher U. , Galloway, Thomas J. , Yom, Sue S. , Kudrimoti, Mahesh , Kim, Harold E., Harris, Jonathan , Le, Quynh‐Thu , Holmes, Brittany J , Zevallos, Jose , Holsinger, F Chris , Emami, Bahman , Jordan, Richard C , Hayward, Michele C , Sagar, Stephen M , Morrison, William , Schultz, Christopher , Caudell, Jimmy J , Jones, Christopher U , Bratman, Scott V , Galloway, Thomas J , Ma, Daniel , Yom, Sue S , Kudrimoti, Mahesh , Kim, Harold E , Harris, Jonathan , Le, Quynh-Thu , Hayes, D Neil , Diehn, Maximillian , Holsinger, F. Christopher , Daniel, J.

Mayo Clinic

Clinical Cancer Research | December 10, 2024 | Volume: 31 | Issue: 9 | Pages: 1615-1624

10.1158/1078-0432.ccr-24-2334 | PMID 39656603 Get It

Abstract Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging because of multimodality treatment regimens. This study aims to investigate the association between NFE2L2/KEAP1/CUL3 mutations and patient outcomes, including local failure, locoregional failure, disease-free survival (DFS), and overall survival, using samples from a phase III trial in which patients were treated with radiation monotherapy at two controlled doses. Patients and Methods: We investigated NFE2L2/KEAP1/CUL3 mutations in 250 randomized patients with T2N0 glottic squamous cell carcinoma receiving definitive radiotherapy in the NRG/RTOG 9512 trial. A total of 119 patients had available biospecimens that were subjected to amplicon-based next-generation sequencing to assess for the presence of NFE2L2/KEAP1/CUL3 mutations without regard to outcomes. Mutations in NFE2L2/KEAP1/CUL3 were assessed blinded to clinical outcomes. Cox models (two-sided α = 0.05) were used to evaluate the association with clinical outcomes, performed by an independent statistical team. Results: Nineteen of 119 patients (16.0%) had NFE2L2/KEAP1/CUL3 mutations. Patient, treatment, and tumor characteristics were similar between those with and without mutations. Patients with mutation compared with those without had significantly more local failure [HR = 3.50; 95% confidence interval (CI), 1.56–7.89; P = 0.0025] and locoregional failure (HR = 3.80; 95% CI, 1.80–8.03; P = 0.0005). DFS was significantly worse for the mutated compared with the nonmutated group in the first 2 years (HR = 2.88; 95% CI, 1.46–5.66; P = 0.0022). The median DFS was shorter in the mutation group (10.3 months) versus those with intact NFE2L2/KEAP1/CUL3 (4.2 years). Conclusions: NFE2L2/KEAP1/CUL3 mutations may predict radiation treatment failure in T2N0 glottic cancer. See related commentary by Rao, p. 1563
A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes
Hirsch, Irl B. , Beck, Roy W. , Marak, Martin Chase , Kudva, Yogish C. , Aktürk, Halis Kaan , Bhargava, Anuj , Codorniz, Kevin , Diner, Jamie, Aleppo, Grazia , Blevins, Thomas , Raskin, Philip, Castorino, Kristin , Manessis, Anastasios , Pickering, David, Weinstock, Ruth S. , Bode, Bruce W. , Nguyen, Quang T., Kipnes, Mark, Ruedy, Katrina J., Desjardins, Donna, Haider, Zehra, Jacobson, Christopher , Klein, Klara R. , O’Malley, Grenye , Church, Mei Mei , Mottalib, Adham , Baran, Jesica D., Kurek, Corey, Rizvi, Shafaq, Donahue, Cassandra, Tamarez, Denisa, Atakov-Castillo, Astrid , Borgman, Sarah, Frey, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Akturk, Halis K., Beatson, Christie , Mason, E E , Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, Levister, Camilla, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Mottalib, Adham, Salah, Tareq , Badri, Marwa Al, Nguyen, Quang T., Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, Manessis, Anastasios, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Castorino, Kristin, Church, Mei Mei, Thorsell, Ashley, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Bzdick, Suzan, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Ghorbani, Tahereh, Young, Laura , Donahue, Cassandra, Kass, Alexander, Fulghum, Karla, Raskin, Philip, Jordan, Lin, Shao, Baomei, Hirsch, Irl B., Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Kudva, Yogish C. , Akturk, Halis K , Levy, Carol J , Castorino, Kristin , Steenkamp, Devin W , Weinstock, Ruth S , Hamdy, Osama , Klein, Klara R , Church, Mei Mei , Mottalib, Adham , Calhoun, Peter , Hirsch, Irl B , Aleppo, Grazia , Beck, Roy W , Levy, Carol J. , Nguyen, Quang T., Lee, Scott Jeffery , Buse, John B. , Donahue, Cassandra, Borgman, Sarah, Calhoun, Peter , Group, INHALE-3 Study, Akturk, Halis K., Mason, Emma, Bauman, Shannon, Mottalib, Adham, Dhaver, Shilton , Nguyen, Quang T., Manessis, Anastasios, Castorino, Kristin, Church, Mei Mei, Johnson, Olivia, Coviello, Andrea D. , Donahue, Cassandra, Raskin, Philip, Hirsch, Irl B., Ulloa, Johanna, Frey, Sarah, Miller, Paige, McCarthy, Chris

Mayo Clinic

Diabetes Care | December 6, 2024 | Volume: 48 | Issue: 3 | Pages: 353-360

10.2337/dc24-1832 | PMID 39641970 Get It

OBJECTIVE To evaluate a regimen of inhaled Technosphere insulin (TI) plus insulin degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring. RESEARCH DESIGN AND METHODS At 19 sites, adults with type 1 diabetes were randomly assigned to TI plus insulin degludec (N = 62) or usual care (UC) with continuation of prestudy insulin delivery method (N = 61) for 17 weeks. RESULTS Prestudy, AID was used by 48% and MDI by 45%. Mean ± SD HbA1c was 7.57% ± 0.97% at baseline and 7.62% ± 1.06% at 17 weeks in the TI group and 7.59% ± 0.80% and 7.54% ± 0.77%, respectively, in the UC group (adjusted difference 0.11%, 95% CI −0.10 to 0.33, P value for noninferiority = 0.01). HbA1c improved from baseline to 17 weeks by >0.5% (5.5 mmol/mol) in 12 (21%) in the TI group and in 3 (5%) in the UC group and worsened by >0.5% (5.5 mmol/mol) in 15 (26%) in the TI group and in 2 (3%) in the UC group. The most common TI side effect was a brief cough; eight participants discontinued TI due to side effects. CONCLUSIONS In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.
Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma
Romero, Alexis, Nguyen, Sophia, Ayers, Amy , Chen, Minxing , Yzquierdo, Rebecca, Rahman, Adiya, Johnson, Lauren, Vickers, Tiffany, Wafi, Zeinab, Flowers, Christopher R. , Romero, Alexis, Andersen, Clark R. , Rahman, Adiya, Johnson, Lauren, Vickers, Tiffany, McNeill, Lorna Haughton. , Cerhan, James R. , Nze, Chijioke

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3733-3733

10.1182/blood-2024-211657 Get It

Background Hispanic patients continue to be underrepresented in clinical trials. To better understand the factors that impact clinical trial participation, we surveyed patients with NHL receiving care at an academic institution on their perspectives on clinical trials, barriers to care, and helpful aids to encourage clinical trial participation. Here we report the findings of the Hispanic patients and non-Hispanic white patients; accrual is ongoing for other cohorts of patients. Methods Consecutive patients ≥ 18 years old with histologically confirmed NHL who received care at MD Anderson Cancer Center in the Texas Medical Center in Houston, Texas were invited to participate regardless of treatment status. A self-administered questionnaire was used to assess patient sociodemographic factors, perceptions and willingness to participate in different clinical trial scenarios as well as participant perceived barriers to care and facilitators of trial participation. The questionnaire included a total of 53 items with an additional 13 demographic items. The questionnaire was available in English and Spanish. Results Of the 1204 patients invited, 316 consented to participate and 285 ultimately completed the survey (participation rate 23.7%). Among the total participants, this cohort included 100 self-identified Hispanic (H) participants and 103 non-Hispanic white (NHW) participants diagnosed with NHL who completed the survey and were included here. The histology of our cohort included Follicular Lymphoma (FL) [35.6%]; Diffuse Large B-cell lymphoma (DLBCL) [18.2%], Mantle cell lymphoma (MCL) [18.7%], T-cell Lymphoma (TCL) [9.4%] Marginal Zone Lymphoma [7.8%]. Compared with NHW participants, Hispanic patients were younger (Median age of 60 vs 66 years), less likely to be male (H 54% vs NHW 66%), less likely to commute more than an hour away from the doctor's office (54% vs 71.8%), had lower household income (income > $100,000 was 32% vs 41.7%) and less likely to have a bachelors' degree or higher (38% vs 50.5%). There were similar prevalence histologies such as DLBCL (H 20% vs NHW 16.5%) and FL (H 36% vs NHW 35%) compared to rarer histologies such as MCL (H 11.1% vs NHW 26.2%) and MZL (H 12% vs NHW 3.9% ) which had disproportional prevalences. Hispanic patients were less likely to have previously participated in a clinical trial (28% vs 51.5%) and less likely to have discussed clinical trials as an option (49% vs 70.9%). A majority of Hispanic (81.0%) and NHW (92.3%) respondents stated that they understood what was meant by a “clinical research study” or “clinical trial” somewhat well or very well. Less than half of Hispanic participants (38.0%) and NHW participants (48.5%) reported being very willing to participate in a cancer clinical trial as their initial course of treatment. The most prevalent concern of both Hispanic and NHW participants respectively was the cost of a clinical trial (34.0%, 22.3%). Other top concerns included distance to the treatment center (32.0%, 13.6%) and frequency of contact with the care team (26.0%, 14.6%). Participants identified access to written materials (69.0%, 60.2%), insurance aid (65.0%, 68.0%), and access to videos (64.0%, 51.5%) as extremely helpful resources that could reduce the burden of participating in a clinical trial. Participants identified that it was most important that a treatment may improve their quality of life by decreasing pain level, increasing activity level, or other symptoms (76.0%, 91.3%). Conclusions Although most Hispanic and NHW participants reported a very good understanding of clinical trials and similar facilitators/barriers for trial participation, Hispanic patients were less likely to have discussed trials as an option with their care teams and less likely to have previously participated in a trial. Evidence-based interventions to address various barriers to clinical trials exist but data on their effectiveness and application is limited. Implementing strategically designed evidence-based interventions to address identified barriers and facilitators will be necessary to improve participation in lymphoma clinical trials.
Factors Influencing Clinical Trial Participation Among Patients with Non-Hodgkin Lymphoma Receiving Care in a Safety Net Hospital
Romero, Alexis, Nguyen, Sophia, Ayers, Amy , Yzquierdo, Rebecca, Ma, Hilary , Overman, Michael J. , Flowers, Christopher R. , Romero, Alexis, McNeill, Lorna Haughton. , Cerhan, James R. , Nze, Chijioke

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3746-3746

10.1182/blood-2024-211976 Get It

Background Underserved patient populations characterized by low income, lack of insurance, low levels of education, and minoritized status face significant barriers when accessing clinical trials. To better understand these challenges, patients from a safety-net county hospital were surveyed on their perspectives on clinical trials, barriers to care, and facilitators of participation. Methods Patients ≥ 18 years old with histologically confirmed non-Hodgkin lymphoma (NHL) who received care at Lyndon B. Johnson Hospital, a safety-net county hospital in Houston, Texas, were invited to participate regardless of treatment status. A self-administered questionnaire was used and offered in English or Spanish. The questionnaire included a total of 53 items with an additional 13 demographic items assessing patient sociodemographic factors and knowledge of clinical trials. Questions also addressed barriers/facilitators of trial participation and respondent willingness to participate in a trial based on certain scenarios. Results Of the 136 patients invited to participate, a total of 49 participants diagnosed with NHL consented to the study and all completed the survey (participation rate 36%). Twenty-seven (55%) surveys were completed in Spanish. Participants self-identified as Hispanic (N=35, 71.4%), African American (N=6, 12.2%), non-Hispanic white (N=7, 14.3%), and Asian/Pacific Islander (N=1, 2%). This cohort included Diffuse Large B-cell lymphoma NOS (DLBCL) [32%], Follicular Lymphoma (FL) [28%], Marginal Zone lymphoma (12%). There were several patients with rare histologies such as Burkitt's lymphoma (4.2%); Mantle Cell lymphoma (4.2%), Plasmablastic lymphoma (4.2%) and T-cell lymphoma (4.1%). The majority of participants reported a commute of less than an hour away to the doctor's office (83%) with almost all participants commuting less than 2 hours (98% with 2% missing an answer). Participants were a median age of 55 years old (range 22-80), majority female (51%), less than a bachelor's degree as highest education (91.8%) and earning < $35,000 (49%). Among respondents, 89.8% had not participated in a clinical trial for their cancer. Only 36.7% of respondents reported that they understood what a clinical research study as “somewhat well,” while 30.6% reported their understanding as “not very well.” Regardless, a majority were very willing (38.8%) or somewhat willing (36.7%) to participate in a trial as their initial course of treatment. Respondents' biggest concerns were the cost of a clinical trial (61.2%), not being able to contact the research team with questions (38.8%), and frequency of clinic visits (32.7%). The most helpful resources that participants identified to reduce participation burden were educational resources such as written materials (77.6%), videos (67.3%), an explanation of the study in their language (65.3%), insurance aid (75.5%), and flexible study visit times (65.3%). Notably, 26.5% of participants responded that they believed they had received medication from a doctor as part of an experiment without their permission. When asked which outcome would most influence their decision to participate in a trial, 79.6% of participants rated the possibility of improving quality of life by decreasing pain and increasing activity levels as very important. Fewer patients (55%) rated other outcomes such as types of side effects (55%) and possibility of pain/discomfort (59%) as very important. Conclusions The majority of patients with NHL who participated in this observational study had little or no previous exposure to or understanding of cancer clinical trials. We identified common barriers to participation including out-of-pocket costs, the ability to contact the research team, and the frequency of clinic visits that should be addressed with specific identified resources to reduce participation burden. Interventions guided by these data should be implemented and evaluated to improve clinical trial participation for patients with lymphoma.